Race and CD4⁺ T-cell count in HIV prognosis and treatment

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA panel. JAMA300(5),555–570 (2008).
  Medline CASGoogle Scholar
• 2  Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, Mckenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years – United States, 2008. MMWR Recomm. Rep.57(RR-10),1–12 (2008).
  MedlineGoogle Scholar
• 3  Achhra AC, Amin J, Law MG et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS24(12),1877–1886 (2010).
  MedlineGoogle Scholar
• 4  Baker JV, Peng G, Rapkin J et al. CD4⁺ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS22(7),841–848 (2008).
  MedlineGoogle Scholar
• 5  Bussmann H, Wester CW, Masupu KV et al. Low CD4⁺ T-Lymphocyte values in human immunodeficiency virus-negative adults in Botswana. Clin. Diagn. Lab. Immunol.11(5),930–935 (2004).
  MedlineGoogle Scholar
• 6  Chng WJ, Tan GB, Kuperan P. Establishment of adult peripheral blood lymphocyte subset reference range for an Asian population by single-platform flow cytometry: influence of age, sex, and race and comparison with other published studies. Clin. Diagn. Lab. Immunol.11(1),168–173 (2004).
  MedlineGoogle Scholar
• 7  Das BR, Bhanushali AA, Khadapkar R, Jeswani KD, Bhavsar M, Dasgupta A. Reference ranges for lymphocyte subsets in adults from western India: influence of sex, age and method of enumeration. Indian J. Med. Sci.62(10),397–406 (2008).
  MedlineGoogle Scholar
• 8  Jiang W, Kang L, Lu HZ et al. Normal values for CD4 and CD8 lymphocyte subsets in healthy Chinese adults from Shanghai. Clin. Diagn. Lab. Immunol.11(4),811–813 (2004).
  MedlineGoogle Scholar
• 9  Kibaya RS, Bautista CT, Sawe FK et al. Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS One3(10),E3327 (2008).
  MedlineGoogle Scholar
• 10  Lugada ES, Mermin J, Kaharuza F et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin. Diagn. Lab. Immunol.11(1),29–34 (2004).
  MedlineGoogle Scholar
• 11  Menard D, Mandeng MJ, Tothy MB, Kelembho EK, Gresenguet G, Talarmin A. Immunohematological reference ranges for adults from the Central African Republic. Clin. Diagn. Lab. Immunol.10(3),443–445 (2003).
  MedlineGoogle Scholar
• 12  Tsegaye A, Wolday D, Otto S et al. Immunophenotyping of blood lymphocytes at birth, during childhood, and during adulthood in HIV-1-uninfected Ethiopians. Clin. Immunol.109(3),338–346 (2003).
  Medline CASGoogle Scholar
• 13  Webster HK, Pattanapanyasat K, Phanupak P et al. Lymphocyte immunophenotype reference ranges in healthy Thai adults: implications for management of HIV/AIDS in Thailand. Southeast Asian J. Trop. Med. Public Health.27(3),418–429 (1996).
  Medline CASGoogle Scholar
• 14  Bofill M, Janossy G, Lee CA et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin. Exp. Immunol.88(2),243–252 (1992).
  Medline CASGoogle Scholar
• 15  Kam KM, Wong KH, Lee SS. Interpretation of CD4⁺ T-lymphocyte values in different HIV-infected populations. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.17(2),185–186 (1998).
  Medline CASGoogle Scholar
• 16  Achhra AC, Zhou J, Dabis F et al. Difference in absolute CD4⁺ count according to CD4 percentage between Asian and Caucasian HIV-infected patients. J. AIDS Clin. Res.1(1),1–4 (2010).
  MedlineGoogle Scholar
• 17  Anglaret X, Diagbouga S, Mortier E et al. CD4⁺ T-lymphocyte counts in HIV infection: are European standards applicable to African patients? J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.14(4),361–367 (1997).
  Medline CASGoogle Scholar
• 18  Hall HI, Song R, Rhodes P et al. Estimation of HIV Incidence in the United States. JAMA300(5),520–529 (2008).
  Medline CASGoogle Scholar
• 19  Blair JM, Fleming PL, Karon JM. Trends in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990–1999. J. Acquir. Immune Defic. Syndr.31(3),339–347 (2002).
  MedlineGoogle Scholar
• 20  Centers for Disease Control and Prevention (CDC). HIV surveillance – United States, 1981–2008. MMWR Morb. Mortal. Wkly Rep.60(21),689–693 (2011).
  MedlineGoogle Scholar
• 21  Burchard EG, Ziv E, Coyle N et al. The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J. Med.348(12),1170–1175 (2003).
  MedlineGoogle Scholar
• 22  Collins FS. What we do and don’t know about ‘race’, ‘ethnicity’, genetics and health at the dawn of the genome era. Nat. Genet.36(11 Suppl.),S13–S15 (2004).
  Medline CASGoogle Scholar
• 23  Lin SS, Kelsey JL. Use of race and ethnicity in epidemiologic research: concepts, methodological issues, and suggestions for research. Epidemiol. Rev.22(2),187–202 (2000).
  Medline CASGoogle Scholar
• 24  Agyemang C, Bhopal R, Bruijnzeels M. Negro, Black, Black African, African Caribbean, African American or what? Labelling African origin populations in the health arena in the 21st century. J. Epidemiol. Community Health59(12),1014–1018 (2005).
  MedlineGoogle Scholar
• 25  Matheron S, Pueyo S, Damond F et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS17(18),2593–2601 (2003).
  MedlineGoogle Scholar
• 26  Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The Challenge of HIV-1 Subtype Diversity. N. Engl. J. Med.358(15),1590–1602 (2008).
  Medline CASGoogle Scholar
• 27  Giordano TP, Bartsch G, Zhang Y et al. Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial. AIDS Patient Care STDS24(5),287–295 (2010).
  MedlineGoogle Scholar
• 28  Easterbrook PJ, Farzadegan H, Hoover DR et al. Racial differences in rate of CD4 decline in HIV-1-infected homosexual men. AIDS10(10),1147–1155 (1996).
  Medline CASGoogle Scholar
• 29  Anastos K, Gange SJ, Lau B et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J. Acquir. Immune Defic. Syndr.24(3),218–226 (2000).
  Medline CASGoogle Scholar
• 30  Mekonnen Y, Geskus RB, Hendriks JCM et al. Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers. J. Infect. Dis.192(5),739–748 (2005).▪▪ Provides evidence that lower preseroconversion CD4+ counts and slower rate of CD4+ decline after HIV infection in blacks compared with whites does not translate into differential risk of AIDS or death in the two races.
  MedlineGoogle Scholar
• 31  May M, Wood R, Myer L et al. CD4⁺ T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland. J. Infect. Dis.200(11),1729–1735 (2009).▪▪ Analyzed South African and Swiss cohorts with comparable methodology, showing that irrespective of the geographical region, untreated HIV infection resulted in a slower rate of CD4+ count decline in blacks compared with whites, especially at higher CD4+ counts.
  MedlineGoogle Scholar
• 32  Weintrob AC, Grandits GA, Agan BK et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J. Acquir. Immune. Defic Syndr.52(5),574–580 (2009).
  Medline CASGoogle Scholar
• 33  Müller V, Von Wyl V, Yerly S et al. African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS23(10),1269–1276 (2009).
  Medline CASGoogle Scholar
• 34  Keller M, Lu Y, Lalonde RG, Klein MB. Impact of HIV-1 viral subtype on CD4⁺ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS23(6),731–737 (2009).
  MedlineGoogle Scholar
• 35  Lewden C, Thiebaut R, Boufassa F et al. Comparison of early CD4 T-cell count in HIV-1 seroconverters in Cote d’Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts. J. Acquir. Immune. Defic. Syndr.53(2),260–265 (2010).
  MedlineGoogle Scholar
• 36  Pantazis N, Morrison C, Amornkul P et al. Longitudinal CD4 cell count evolution during HIV natural history: comparison between European and sub-Saharan African seroconverter cohorts. Presented at: The 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, February 2010. Abstract 978.
  Google Scholar
• 37  Meditz AL, Mawhinney S, Allshouse A et al. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J. Infect. Dis.203(4),442–451 (2011).
  MedlineGoogle Scholar
• 38  Wandel S, Egger M, Rangsin R et al. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex. Transm. Infect.84(Suppl. 1),i31–i36 (2008).
  MedlineGoogle Scholar
• 39  Zhou J, Kumarasamy N, Ditangco R et al. The TREAT Asia HIV observational database: baseline and retrospective data. J. Acquir. Immune Defic. Syndr.38(2),174–179 (2005).
  MedlineGoogle Scholar
• 40  Minga AK, Lewden C, Gabillard D et al. CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters. AIDS25(6),819–823 (2011).
  Medline CASGoogle Scholar
• 41  Ng OT, Lin L, Laeyendecker O et al. Increased rate of CD4⁺ T-cell decline and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected seroconverters in Singapore. PLoS One6(1),E15738 (2011).
  MedlineGoogle Scholar
• 42  Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science317(5840),944–947 (2007).
  Medline CASGoogle Scholar
• 43  Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect. Dis.6(5),280–287 (2006).
  Medline CASGoogle Scholar
• 44  Mocroft A, Phillips AN, Gatell J et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet370(9585),407–413 (2007).
  Medline CASGoogle Scholar
• 45  Gras L, Kesselring AM, Griffin JT et al. CD4 cell counts of 800 cells/mm³ or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm³ or greater. J. Acquir. Immune Defic. Syndr.45(2),183–192 (2007).
  MedlineGoogle Scholar
• 46  Achhra AC, Phanuphak P, Amin J. Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries. Curr. Opin. HIV AIDS6(4),258–265 (2011).
  MedlineGoogle Scholar
• 47  Silverberg MJ, Wegner SA, Milazzo MJ et al. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS20(11),1531–1538 (2006).▪ One of the few North American studies accounting for access to care and adherence in blacks and white populations, showing comparable outcomes after antiretroviral therapy by race.
  Medline CASGoogle Scholar
• 48  Egger S, Petoumenos K, Kamarulzaman A et al. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J. Acquir. Immune Defic. Syndr.50(5),513–520 (2009).▪▪ One of the few studies providing a direct comparision of CD4+ count responses to antiretroviral therapy between white and Asian individuals.
  MedlineGoogle Scholar
• 49  Jensen-Fangel S, Pedersen L, Pedersen C et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin. Infect. Dis.35(12),1541–1548 (2002).
  MedlineGoogle Scholar
• 50  Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS16(8),1139–1146 (2002).
  Medline CASGoogle Scholar
• 51  Giordano TP, Wright JA, Hasan MQ, White AC, Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin. Infect. Dis.37(3),433–437 (2003).
  MedlineGoogle Scholar
• 52  Kulkarni H, Okulicz JF, Grandits G et al. Early post-seroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr.57(5),387–395 (2011).
  Medline CASGoogle Scholar
• 53  Staehelin C, Rickenbach M, Low N et al. Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS17(15),2237–2244 (2003).
  MedlineGoogle Scholar
• 54  Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N. Engl. J. Med.333(12),751–756 (1995).
  Medline CASGoogle Scholar
• 55  McGinnis KA, Fine MJ, Sharma RK et al. Understanding racial disparities in HIV using data from the Veterans Aging Cohort 3-Site Study and VA administrative data. Am. J. Public Health93(10),1728–1733 (2003).
  MedlineGoogle Scholar
• 56  Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for Initial HIV therapy: results of ACTG A5095. J. Acquir. Immune Defic. Syndr.46(5),547–554 (2007).
  Medline CASGoogle Scholar
• 57  Anastos K, Schneider MF, Gange SJ et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J. Acquir. Immune Defic. Syndr.39(5),537–544 (2005).▪ This study, along with [58], shows that psychosocial and socioeconomic factors are the most important factors influencing the disparities in outcomes between blacks and whites.
  Medline CASGoogle Scholar
• 58  Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ: The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J. Acquir. Immune Defic. Syndr.47(2),194–201, (2008).▪ This study, along with [57], shows that psychosocial and socioeconomic factors are the most important factors influencing the disparities in outcomes between blacks and whites.
  MedlineGoogle Scholar
• 59  Pérez Molina JA, Rillo MM, Suárez-Lozano I et al. Do HIV-infected immigrants initiating HAART have poorer treatment-related outcomes than autochthonous patients in Spain? Results of the GESIDA 5808 study. Curr. HIV Res.8(7),521–530 (2010).
  Medline CASGoogle Scholar
• 60  Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med.360(18),1815–1826 (2009).
  Medline CASGoogle Scholar
• 61  Severe P, Jean Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N. Engl. J. Med.363(3),257–265 (2010).
  Medline CASGoogle Scholar
• 62  The HIV–Causal Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries. Ann. Intern. Med.154(8),509–515 (2011).
  MedlineGoogle Scholar
• 63  The Strategies for Management of Antiretroviral Therapy Study Group. Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving art at baseline in the SMART study. J. Infect. Dis.197(8),1133–1144 (2008).
  MedlineGoogle Scholar
• 64  When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet373(9672),1352–1363 (2009).
  MedlineGoogle Scholar
• 65  Silverberg M, Leyden W, Quesenberry C, Horberg M. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J. Gen. Intern. Med.24(9),1065–1072 (2009).
  MedlineGoogle Scholar
• 66  Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet367(9513),817–824 (2006).
  MedlineGoogle Scholar
• 67  Brinkhof MWG, Egger M, Schechter M, Dabis F. Mortality of HIV-infected patients in low-income countries – authors’ response. Lancet368(9554),2207–2208 (2006).
  MedlineGoogle Scholar
• 68  Kadhiravan T, Sharma SK. Mortality of HIV-infected patients in low-income countries. Lancet368(9554),2207–2207 (2006).
  MedlineGoogle Scholar
• 69  Chen NE, Gallant JE, Page KR. A systematic review of HIV/AIDS survival and delayed diagnosis among Hispanics in the United States. J. Immigr. Minor. Health14(1),65–81 (2012).
  MedlineGoogle Scholar
• 70  Achhra AC, Zhou J, Choi JY et al. The clinical significance of CD4 counts in Asian and Caucasian HIV-infected populations: results from TAHOD and AHOD. J. Int. Assoc. Physicians AIDS Care (Chic.)10(3),160–170 (2011).▪ One of the few studies comparing Asians and white populations. Provides direct evidence for the similar magnitude of risk of AIDS or death at any given CD4+ count in Asians and white populations.
  MedlineGoogle Scholar
• 71  Ho CF, Lee SS, Wong KH, Cheng LS, Lam MY. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients. HIV Med.8(3),181–185 (2007).
  MedlineGoogle Scholar
• 72  Wong KH, Chan KC, Cheng KL, Chan WK, Kam KM, Lee SS. Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong. AIDS Patient Care STDS21(2),106–115 (2007).
  MedlineGoogle Scholar
• 101  WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach, 2011. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf (Accessed 15 September 2011)
  Google Scholar
• 102  WHO. Facts about health in the African region of WHO, 2011. www.afro.who.int/index.php?option=com_content&view=article&id=87&Itemid=563 (Accessed 15 August 2011)
  Google Scholar
• 103  WHO. HIV/AIDS in the south-east Asia region, 2009. www.searo.who.int/LinkFiles/Publications_HIV_AIDS_Report2009.pdf (Accessed 15 August 2010)
  Google Scholar
• 104  Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2011. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Accessed 18 August 2011)
  Google Scholar
• 105  Strategic Timing of Antiretroviral Treatment (START). http://clinicaltrials.gov/ct2/show/NCT00867048 (Accessed 18 August 2011)
  Google Scholar